Table 3 Exposure to all types- and major-pDDIs stratified with respect to patients’ characteristics
From: Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?
Patient’s characteristics | All types of interactions | Only major interactions |
|---|---|---|
Patients: n (%) | Patients: n (%) | |
Gender | ||
 Male | 162 (51.4) | 121 (52.2) |
 Female | 153 (48.6) | 111 (47.8) |
Age (years) | ||
 ≤30 | 19 (6) | 13 (5.6) |
 31–60 | 154 (48.9) | 116 (50) |
 >60 | 142 (45.1) | 103 (44.4) |
Drugs prescribed per patient | ||
 ≤5 | 7 (2.2) | 1 (0.4) |
 6–10 | 103 (32.7) | 60 (25.9) |
 >10 | 205 (65.1) | 171 (73.7) |
Hospital stay (days) | ||
 ≤2 | 47 (14.9) | 28 (12.1) |
 3–4 | 97 (30.8) | 71 (30.6) |
 >4 | 171 (54.3) | 133 (57.3) |
Comorbidities | ||
 Hypertension | 173 (54.9) | 128 (55.2) |
 Diabetes mellitus | 102 (32.4) | 77 (33.2) |
 Stroke | 98 (31.1) | 75 (32.3) |
 Chronic obstructive pulmonary disease | 25 (7.9) | 13 (5.6) |
 Ischemic heart disease | 30 (9.5) | 25 (10.8) |
 Urinary tract infection | 25 (7.9) | 21 (9.1) |
 Tuberculosis | 22 (7) | 21 (9.1) |
 Hepatitis | 16 (5.1) | 11 (4.7) |
 Chronic kidney disease | 16 (5.1) | 9 (3.9) |
 Asthma | 14 (4.4) | 10 (4.3) |